Drug Study day AUC (µg/mL*h) Cmax (µg/mL) tmax (h) Cmin (µg/mL) tmin (h)
Rifampicin D 15 27.64 (13.19-39.77) 5.05 (3.30-6.23) 3.00 (2.00-4.00) 0.0 (0.0-0.0) 0.0 (0.0-0.0)
  D 45 34.35 (22.39-58.19) 5.05 (4.22-8.21) 1.50 (1.00-2.00) 0.0 (0.0-0.0) 0.0 (0.0-0.0)
  D90 34.39 (32.71-61.80) 5.88 (5.81-8.50) 2.00 (1.50-2.00) 0.0 (0.0-0.0) 0.0 (0.0-0.0)
  D180 40.40 (37.84-58.26) 6.51 (6.33-10.81) 2.00 (2.00-4.00) 0.0 (0.0-0.0) 0.0 (0.0-0.0)
Lopinavir D 45 142.95 (112.88-168.85) 14.71 (13.02-20.39) 4.00 (3.50-4.50) 4.64 (2.65-9.85) 12.00 (0.00-12.00)
  D90 179.38 (140.16-182.99) 18.91 (16.37-21.16) 4.00 (3.00-4.00) 8.65 (4.33-10.01) 1.00 (0.50-6.50)
  D180* 123.05 (88.47-154.56) 16.65 (12.04-18.91) 2.00 (1.50-2.00) 0.74 (0.37-5.92) 12.00 (12.00-12.00)
  D180** 173.95 (146.06-201.83) 18.94 (15.86-22.03) 5.00 (3.50-6.50) 9.34 (7.60-11.07) 11.00 (10.50-11.50)
  D 210 119.14 (101.56-133.91) 12.13 (10.58-14.18) 4.00 (4.00-4.50) 4.82 (3.25-6.16) 6.00 (0.00-12.00)
* median values of patients receiving LPV/r 800/200 mg
** median values of patients receiving LPV/r 600/150 mg
Table 3: Summary of the pharmacokinetic for rifampicin and lopinavir, by treatment stage (median, IQR).